Literature DB >> 22055655

Antimicrobial prophylaxis in women with recurrent urinary tract infections.

Paola Lichtenberger1, Thomas M Hooton.   

Abstract

Recurrent urinary tract infections (UTIs) in women are common, result in considerable morbidity and expense, and can be a management problem for clinicians. Behavioural changes can be useful antimicrobial-sparing measures in the prevention of recurrent UTIs, but antimicrobial prophylaxis may be necessary in those who continue to have recurrences. Continuous prophylaxis, post-coital prophylaxis and intermittent self-treatment with antimicrobials have all been demonstrated to be effective in the prevention of recurrent uncomplicated UTIs. The decision as to which approach to use depends upon the frequency and pattern of recurrences and willingness of the patient to commit to a specific regimen. The risk of adverse events, including antimicrobial resistance, patient's lifestyle and compliance and plans for a pregnancy also need to be considered. The choice of antimicrobial should be based upon the susceptibility pattern of the organisms causing the patient's previous UTIs and history of drug allergies.
Copyright © 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22055655     DOI: 10.1016/j.ijantimicag.2011.09.005

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  12 in total

1.  Recurrent urinary tract infections in healthy and nonpregnant women.

Authors:  Matthew Glover; Cristiano G Moreira; Vanessa Sperandio; Philippe Zimmern
Journal:  Urol Sci       Date:  2014-03

2.  Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial.

Authors:  Elisabetta Costantini; Alessandro Zucchi; Eleonora Salvini; Annarita Cicalese; Vincenzo Li Marzi; Maria Teresa Filocamo; Vittorio Bini; Massimo Lazzeri
Journal:  Int Urogynecol J       Date:  2014-02-20       Impact factor: 2.894

3.  Urinary excretion of ciprofloxacin after administration of extended release tablets in healthy volunteers. Swellable drug-polyelectrolyte matrix versus bilayer tablets.

Authors:  M L Guzmán; C B Romañuk; M F Sanchez; L C Luciani Giacobbe; L P Alarcón-Ramirez; F D Battistini; F L Alovero; A F Jimenez-Kairuz; R H Manzo; María Eugenia Olivera
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

4.  Management of recurrent urinary tract infections in healthy adult women.

Authors:  Duane R Hickling; Victor W Nitti
Journal:  Rev Urol       Date:  2013

Review 5.  Recurrent urinary tract infections in women.

Authors:  Abdullatif Aydin; Kamran Ahmed; Iftikhar Zaman; Muhammad Shamim Khan; Prokar Dasgupta
Journal:  Int Urogynecol J       Date:  2014-11-20       Impact factor: 2.894

6.  Determinants of antimicrobial resistance in Escherichia coli strains isolated from faeces and urine of women with recurrent urinary tract infections.

Authors:  Casper D J den Heijer; Mariëlle A J Beerepoot; Jan M Prins; Suzanne E Geerlings; Ellen E Stobberingh
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

7.  Recurrent nitrofurantoin-induced giant cell interstitial pneumonia: Case report and literature review.

Authors:  Boeun Lee; Arvind Balavenkataraman; Devang Sanghavi; Kristin Walter
Journal:  Respir Med Case Rep       Date:  2015-01-29

8.  Unrecognized Interstitial Lung Disease as a Result of Chronic Nitrofurantoin Use.

Authors:  Kerry Anne Rambaran; Charles F Seifert
Journal:  Drug Saf Case Rep       Date:  2016-12

9.  Lower Levels of Urinary Nerve Growth Factor Might Predict Recurrent Urinary Tract Infections in Women.

Authors:  Fei-Chi Chuang; Hsin-Tzu Liu; Hann-Chorng Kuo
Journal:  Int Neurourol J       Date:  2016-03-15       Impact factor: 2.835

10.  Anti-Adhesion Activity of A2-type Proanthocyanidins (a Cranberry Major Component) on Uropathogenic E. coli and P. mirabilis Strains.

Authors:  Daria Nicolosi; Gianna Tempera; Carlo Genovese; Pio M Furneri
Journal:  Antibiotics (Basel)       Date:  2014-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.